Number Т. 9, № 3 (35) 2019

Treatment of renal cell cancer with metastases in lung with dendritic cell auto-vaccine

Sovenco V.M., Skachkova O.V., Hanul A.V., Bororov L.V., Borisiuk B.O., Orel V.Е., Hanul V.A., Shevchenko A.I., Velichko V.V., Firchuk I.I.

Summary. Introduction. In the modern world, the possibility of using targeted therapy and immunotherapy in the treatment of renal cell cancer is being actively explored. New approaches to create effective antitumor immune response stimulators have been discovered to improve the effectiveness of vaccine therapy in patients with metastatic renal cell cancer. Goal. To investigate the safety and efficacy of using dendritic cell (DC) auto-vaccine in renal cell cancer patients. Object and methods of research. In the Research Department of Tumors of the Thoracic Cavity of the National Cancer Institute, we conducted a study of the effectiveness of the use of DC auto-vaccine in patients with renal cell cancer with lung metastases. In the course of our work, we evaluated the safety and toxicity of treatment with DC auto-vaccine of cancer patients with renal cell cancer. The complex method with the inclusion of postoperative injection of DC auto-vaccine treated 10 patients with metastases of renal cell cancer in the lung. The effectiveness and safety of the use of DC auto-vaccine was analyzed. Possibilities for further use of DC auto-vaccine in the complex treatment of patients with renal cell cancer with metastases in the lung were evaluated. Results. The median survival in the main (n=10) group of patients with renal cell cancer with metastases in the lung who underwent postoperative and postoperative DC auto-vaccine was 45.1 months. The median survival in the control (n=10) group of patients was 39.3 months (the difference was not statistically significant; p=0.708). The overall five-year survival of patients in the main group was 78.7%, compared with 69.1% in the control group. Recurrent five-year survival in patients with renal cell cancer metastases to the lung was 69.4 and 60.4% in the main and control groups, respectively (difference statistically unreliable; p=0.605). As can be seen from the results, the use of DC auto-vaccine in the complex treatment of patients with renal cell cancer has shown a tendency to improve survival, but more observations need to be evaluated. Conclusions. The data obtained on the tendency to improve survival allow us to plan further studies in this direction. Carrying out DC auto-vaccination aimed at improving the effectiveness of the treatment of patients with metastases of renal cell cancer in the lung is not accompanied by toxic manifestations and side effects.

No Comments » Add your
Leave a comment